Paper
36 Baseline systemic immune profiles predict prognosis and differential benefit from ipilimumab intensification in relapsed mesothelioma (Bio-IFCT-1501 MAPS2 trial)
Journal for ImmunoTherapy of Cancer · 2026 · Matthieu Roulleaux Dugage, Guillaume Tosato, Aurélien Marabelle et al.